Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate, TSC-101, is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA-2™ Phase 3 pivotal trial). The Company is also in early stages of developing methods for in vivo engineering to treat solid tumors. In addition, the Company is applying its target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Press Releases

View All

Latest Presentations

Events

View All

SEC Filings

Filing date Description Form
Report of unscheduled material events or corporate event 8-K
Quarterly report which provides a continuing view of a company's financial position 10-Q
Official notification to shareholders of matters to be brought to a vote ("Proxy") DEF 14A
View All